EUCTR2005-001231-29-SE进行中（未招募）不适用
A PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED, MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF RITUXIMAB AS INDUCTION THERAPY TOGETHER WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND STEROIDS FOR PATIENTS UNDERGOING RENAL TRANSPLANTATIO
Dept of Transplantation Surgery B 56, Karolinska University Hospital, Huddinge0 个研究点目标入组 140 人开始时间: 2005年7月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients aged 18 years or above
- •Recipients of first or second renal transplant
- •Recipients from living or cadaveric donors
- •Single organ recipients (kidney only)
- •Patients providing written informed consent
- •Patients cooperative and able to complete all the assessment procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •HLA-identical siblings
- •Patients receiving immunosuppressive therapy within the preceding 28 days
- •PRA >50% within 6 months prior to enrolment
- •Previous exposure to murine antibodies
- •History of malignancy (except localised non-melanotic skin cancer) or the presence of any active malignancy at the time of transplant
- •Active infection (HCV, HBV, HIV)
- •Pregnant or lactating females
- •Women of child bearing potential not willing to use reliable form of contraception
研究者
相似试验
进行中（未招募）
不适用
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTRE TRIAL OF ABAGOVOMAB MAINTENANCE THERAPY IN PATIENTS WITH EPITHELIAL OVARIAN CANCER AFTER COMPLETE RESPONSE TO FIRST LINE CHEMOTHERAPYEpithelial Ovarian CancerEUCTR2006-002801-30-HUMENARINI RICERCHE S.p.A870
进行中（未招募）
不适用
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTRE TRIAL OF ABAGOVOMAB MAINTENANCE THERAPY IN PATIENTS WITH EPITHELIAL OVARIAN CANCER AFTER COMPLETE RESPONSE TO FIRST LINE CHEMOTHERAPYEpithelial Ovarian CancerEUCTR2006-002801-30-BEMENARINI RICERCHE S.p.A870
进行中（未招募）
1 期
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTRE TRIAL OF ABAGOVOMAB MAINTENANCE THERAPY IN PATIENTS WITH EPITHELIAL OVARIAN CANCER AFTER COMPLETE RESPONSE TO FIRST LINE CHEMOTHERAPYEpithelial Ovarian CancerEUCTR2006-002801-30-CZMENARINI RICERCHE S.p.A888
进行中（未招募）
不适用
A randomised, double-blind, placebo controlled study to investigate the use of mepolizumab (SB240563) in reducing the need for surgery in subjects with severe bilateral nasal polyposisasal polyposisMedDRA version: 14.1Level: PTClassification code 10028756Term: Nasal polypsSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2008-003772-21-BEGlaxoSmithKline Research & Development Limited110
进行中（未招募）
不适用
A randomised, double-blind, placebo controlled study to investigate the use of mepolizumab (SB240563) in reducing the need for surgery in subjects with severe bilateral nasal polyposisEUCTR2008-003772-21-GBGlaxoSmithKline Research & Development Limited110